[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Resmed Inc (RMD)

Resmed Inc (RMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

ResMed's GLP-1 Shadow Meets Margin Expansion Nobody Expected

ResMed Inc. (RMD) reports fiscal Q4 2026 earnings tomorrow, August 6, after market close, with analysts expecting $2.90 per share on revenue of approximately $1.47 billion. The medical device maker faces a critical test as investors assess whether its momentum in sleep apnea and respiratory care can sustain double-digit growth rates amid rising profitability expectations. With the stock trading near $224 and analyst sentiment recently deteriorating, the report will determine whether ResMed can justify its premium valuation.

ResMed Inc. develops, manufactures, and distributes medical devices for treating sleep-disordered breathing and other respiratory conditions, with its core business focused on continuous positive airway pressure (CPAP) devices,...

Fundamentals

See More
  • Market Capitalization, $K 32,496,892
  • Shares Outstanding, K 145,056
  • Annual Sales, $ 5,146 M
  • Annual Income, $ 1,401 M
  • EBIT $ 1,941 M
  • EBITDA $ 2,177 M
  • 60-Month Beta 0.76
  • Price/Sales 5.93
  • Price/Cash Flow 19.92
  • Price/Book 4.99

Options Overview Details

View History
  • Implied Volatility 48.51% (+0.96%)
  • Historical Volatility 39.70%
  • IV Percentile 99%
  • IV Rank 88.47%
  • IV High 52.18% on 10/30/25
  • IV Low 20.36% on 08/13/25
  • Expected Move (DTE 15) 7.48 (3.32%)
  • Put/Call Vol Ratio 0.28
  • Today's Volume 4,880
  • Volume Avg (30-Day) 1,420
  • Put/Call OI Ratio 1.13
  • Today's Open Interest 19,519
  • Open Int (30-Day) 17,044
  • Expected Range 217.56 to 232.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.90
  • Number of Estimates 6
  • High Estimate $2.95
  • Low Estimate $2.86
  • Prior Year $2.55
  • Growth Rate Est. (year over year) +13.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
190.21 +18.06%
on 07/23/26
226.12 -0.69%
on 08/06/26
+6.16 (+2.82%)
since 07/06/26
3-Month
180.26 +24.57%
on 06/02/26
226.12 -0.69%
on 08/06/26
+14.92 (+7.12%)
since 05/06/26
52-Week
180.26 +24.57%
on 06/02/26
293.81 -23.57%
on 08/22/25
-55.90 (-19.93%)
since 08/06/25

Most Recent Stories

More News
ResMed's GLP-1 Shadow Meets Margin Expansion Nobody Expected

Barchart Research What to Expect from RMD Earnings RMD Generated August 5, 2026 Current Price $224.03 EPS Estimate $$2.90 Consensus Rating Moderate Buy Average Move 4.87% ResMed's GLP-1 Shadow Meets Margin...

RMD : 223.52 (-0.23%)
ResMed (RMD) Q2 Earnings: What To Expect

ResMed (RMD) Q2 Earnings: What To Expect

RMD : 223.52 (-0.23%)
1 Cash-Producing Stock on Our Watchlist and 2 We Find Risky

1 Cash-Producing Stock on Our Watchlist and 2 We Find Risky

ENPH : 39.16 (+0.54%)
RMD : 223.52 (-0.23%)
HAS : 91.44 (+0.31%)
3 Large-Cap Stocks to Consider Right Now

3 Large-Cap Stocks to Consider Right Now

ALL : 273.24 (+3.27%)
INTU : 318.94 (-2.74%)
RMD : 223.52 (-0.23%)
3 Cash-Heavy Stocks to Research Further

3 Cash-Heavy Stocks to Research Further

MYRG : 339.98 (+1.86%)
RMD : 223.52 (-0.23%)
ABNB : 149.30 (-2.09%)
BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)

TROY, Mich. , July 21, 2026 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Broadridge Financial Resources Inc. (NYSE:...

BR : 162.73 (-0.42%)
RMD : 223.52 (-0.23%)
2 Mid-Cap Stocks with Exciting Potential and 1 We Ignore

2 Mid-Cap Stocks with Exciting Potential and 1 We Ignore

RMD : 223.52 (-0.23%)
SNEX : 67.46 (-11.26%)
USFD : 106.18 (+5.66%)
ResMed's Q4 2026 Earnings: What to Expect

ResMed is scheduled to post its fourth-quarter results soon, and analysts project a double-digit earnings growth.

ABT : 107.08 (+1.30%)
XLV : 163.33 (-0.51%)
$SPX : 7,709.57 (-0.18%)
RMD : 223.52 (-0.23%)
Resmed Announces Agreement to Sell MatrixCare Business

SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has entered...

RMD.AX : 31.480 (+0.29%)
RMD : 223.52 (-0.23%)
Why ResMed (RMD) Stock Is Trading Up Today

Why ResMed (RMD) Stock Is Trading Up Today

RMD : 223.52 (-0.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

ResMed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market for generators, masks, and related accessories for the treatment of sleep-disordered breathing (SDB) and other respiratory disorders. SDB includes obstructive sleep apnea (OSA) and other respiratory...

See More

Key Turning Points

3rd Resistance Point 230.37
2nd Resistance Point 227.68
1st Resistance Point 225.86
Last Price 223.52
1st Support Level 221.35
2nd Support Level 218.66
3rd Support Level 216.84

See More

52-Week High 293.81
Fibonacci 61.8% 250.44
Fibonacci 50% 237.04
Fibonacci 38.2% 223.64
Last Price 223.52
52-Week Low 180.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.